Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals
Posted On: 2021-03-09 01:59:19 (Time Zone: Arizona, USA)
Indoco Remedies announces the launch of Brinzolamide Ophthalmic Suspension 1% in the United States, the first generic version of AZOPT® by Teva Pharmaceuticals. The product is developed and manufactured by Indoco Remedies Ltd. for TEVA at its facility in Goa.
The ANDA approved by the US Food and Drug Administration for Brinzolamide Ophthalmic Suspension 1%, is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide Ophthalmic Suspension 1% works by decreasing the amount of fluid within the eye.